Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance

• Published in: Internal Medicine Vol. 61; no. 9; pp. 1337 - 1343
• Main Authors: Kakimoto, Yoshihide, Hoshino, Miyako, Hashimoto, Mikiko, Hiraizumi, Masaya, Shimizu, Kohei, Chou, Takaaki
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01.05.2022; Japan Science and Technology Agency
• Subjects: Adult; adverse drug reaction; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Boron Compounds; Clinical medicine; Dexamethasone; Dexamethasone - therapeutic use; Diarrhea; Diarrhea - chemically induced; Diarrhea - epidemiology; Gastrointestinal diseases; Glycine - analogs & derivatives; Humans; Internal medicine; ixazomib; Japan; Leukopenia - chemically induced; Middle Aged; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - etiology; Nausea; Original; Patients; Peripheral neuropathy; post-marketing all-case surveillance; Product Surveillance, Postmarketing; proteasome inhibitor; Safety; Skin diseases; Surveillance; Thalidomide - therapeutic use; Thrombocytopenia; Thrombocytopenia - chemically induced; Thrombocytopenia - drug therapy; Thrombocytopenia - epidemiology; Japan; multiple myeloma; proteasome inhibitor; adverse drug reaction; safety; ixazomib; post-marketing all-case surveillance

Objective To evaluate the safety profile of ixazomib combined with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) in clinical practice in Japan through an all-case post-marketing surveillance. Methods This was a nationwide non-interventional observational...